Mapi Pharma’s long-acting formulation of glatiramer acetate, GA Depot, may help stabilize disability scores over time in people with both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). That’s according to new analyses of data from an…
GA Depot
A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma…
Recommended Posts
- MSAA expands research network aimed at improving real-world MS care
- Higher ultra-processed food intake tied to increased MS risk: Study
- Patient voices echo strong call for better MS medical care
- CMSC 2026: Kesimpta outperforms Aubagio in highly active relapsing MS
- AI partnership aims to sharpen brain scans’ detection of MS